Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by V Square Quantitative Management LLC

V Square Quantitative Management LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 15,374 shares of the medical research company’s stock after acquiring an additional 348 shares during the quarter. V Square Quantitative Management LLC’s holdings in Edwards Lifesciences were worth $1,138,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wellington Management Group LLP grew its stake in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. State Street Corp grew its stake in shares of Edwards Lifesciences by 1.0% in the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after purchasing an additional 256,538 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after purchasing an additional 284,918 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after purchasing an additional 806,705 shares in the last quarter. Finally, Jennison Associates LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth $555,939,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 0.3 %

Shares of NYSE EW opened at $76.23 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The firm has a market capitalization of $44.96 billion, a PE ratio of 11.00, a PEG ratio of 3.64 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $72.58 and a two-hundred day moving average price of $69.41.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. As a group, analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. The trade was a 12.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock worth $2,002,829 in the last three months. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

EW has been the subject of several recent analyst reports. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $82.00 to $90.00 in a report on Monday, December 16th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and a consensus target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.